Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens
出版年份 2019 全文链接
标题
Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens
作者
关键词
-
出版物
Nature Microbiology
Volume 5, Issue 1, Pages 67-75
出版商
Springer Science and Business Media LLC
发表日期
2019-11-19
DOI
10.1038/s41564-019-0604-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis
- (2019) Evijola Llabani et al. Nature Chemistry
- The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics
- (2018) Michelle F. Richter et al. Annals of the New York Academy of Sciences
- Discovery and development of new antibacterial drugs: learning from experience?
- (2018) Nicole Jackson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibacterial Drug Discovery: Some Assembly Required
- (2018) Rubén Tommasi et al. ACS Infectious Diseases
- Siderophore Conjugates of Daptomycin are Potent Inhibitors of Carbapenem Resistant Strains of Acinetobacter baumannii
- (2018) Manuka Ghosh et al. ACS Infectious Diseases
- Analysis of the clinical antibacterial and antituberculosis pipeline
- (2018) Ursula Theuretzbacher et al. LANCET INFECTIOUS DISEASES
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
- (2018) Alessandro Cassini et al. LANCET INFECTIOUS DISEASES
- Predictive compound accumulation rules yield a broad-spectrum antibiotic
- (2017) Michelle F. Richter et al. NATURE
- Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities
- (2015) B. Hafkin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
- (2015) Xian-Zhi Li et al. CLINICAL MICROBIOLOGY REVIEWS
- ESKAPEing the labyrinth of antibacterial discovery
- (2015) Ruben Tommasi et al. NATURE REVIEWS DRUG DISCOVERY
- A Small Molecule that Induces Intrinsic Pathway Apoptosis with Unparalleled Speed
- (2015) Rahul Palchaudhuri et al. Cell Reports
- Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors
- (2014) Mohamed Takhi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Resistance to AFN-1252 Arises from Missense Mutations inStaphylococcus aureusEnoyl-acyl Carrier Protein Reductase (FabI)
- (2013) Jiangwei Yao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model
- (2013) Mary A Banevicius et al. JOURNAL OF CHEMOTHERAPY
- Platforms for antibiotic discovery
- (2013) Kim Lewis NATURE REVIEWS DRUG DISCOVERY
- Mode of Action,In VitroActivity, andIn VivoEfficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor
- (2012) Nachum Kaplan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Challenges of Antibacterial Discovery
- (2011) L. L. Silver CLINICAL MICROBIOLOGY REVIEWS
- Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?
- (2011) Joshua B Parsons et al. CURRENT OPINION IN MICROBIOLOGY
- Open Babel: An open chemical toolbox
- (2011) Noel M O'Boyle et al. Journal of Cheminformatics
- AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
- (2009) J. A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Triclosan Resistance of Pseudomonas aeruginosa PAO1 Is Due to FabV, a Triclosan-Resistant Enoyl-Acyl Carrier Protein Reductase
- (2009) L. Zhu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI
- (2009) Jailall Ramnauth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI)
- (2009) Peter B. Sampson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
- (2008) Louis B. Rice JOURNAL OF INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now